Follow The Filings

TENX Tenax Therapeutics Inc.

Health Care, filed as TENAX THERAPEUTICS INC (COM NEW), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.6%
  • $3.9M

Who owns this now

Largest portfolio weights among holders, up to 0.6% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke 0.62%

Who owns TENX

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 0.62% Hold 265,934 $3.9M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by TENX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TENX insider trades
  • $6.6M bought by 7 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $1.5M 922,849 shares at $1.59 +14% to stake
    Traded Oct 19–21 Filed Oct 21
  2. Declan Doogan Director
    Buy
    $102K 53,000 shares at $1.92 +2331% to stake
    Traded Sep 16 Filed Sep 17
  3. Christopher Thomas Giordano CEO
    Buy
    $20K 10,850 shares at $1.85 +96% to stake
    Traded Sep 11–15 Filed Sep 15
  4. Thomas R Staab II CFO
    Buy
    $11K 5,675 shares at $1.94 +57% to stake
    Traded Sep 11 Filed Sep 15
  5. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $1.6M 900,000 shares at $1.78 +16% to stake
    Traded Sep 3 Filed Sep 8
  6. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $1.4M 770,333 shares at $1.79 +16% to stake
    Traded Aug 31–Sep 2 Filed Sep 2
  7. ADAR1 Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $1.8M 1,025,867 shares at $1.77 +27% to stake
    Traded Aug 20–24 Filed Aug 24
  8. Stuart Rich Chief Medical Officer
    Buy
    $51K 5,000 shares at $10.16
    Traded Dec 8–9 Filed Dec 10, 2025
  9. Stuart Rich Chief Medical Officer
    Buy
    $46K 5,000 shares at $9.12
    Traded Dec 2–4 Filed Dec 5, 2025
  10. Christopher Thomas Giordano CEO
    Buy
    $20K 2,605 shares at $7.68 New stake
    Traded Nov 18–20 Filed Nov 20, 2025
  11. June Sherie Almenoff Director
    Buy
    $15K 1,993 shares at $7.50 New stake
    Traded Nov 17–18 Filed Nov 20, 2025
  12. Thomas McGauley CFO
    Buy
    $58K 8,000 shares at $7.27
    Traded Nov 17, 2025 Filed Nov 19, 2025

Also filed in the last 12 months, not counted as buying or selling: 2 option exercises and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 8.01,9.01
SCHEDULE 13G/A —
8-K 7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G/A —
8-K 8.01,9.01
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue — $0.00 $0.00
Net income $7.71M -$17.6M -$52.6M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $11.68M $96.69M $104.23M
Total non-current assets * $1,117 $0.00 $0.00
Total assets $11.68M $96.69M $104.23M
Total current liabilities $3.59M $4.69M $7.16M
Total non-current liabilities * $0.00 $0.00 $0.00
Total equity $8.1M $91.99M $97.07M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$5.9M -$14.81M -$35.8M
Cash from investing $2,843 $0.00 —
Cash from financing $13.57M $99.87M $38.51M
Net change in cash * $7.67M $85.06M —

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf